These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28109702)

  • 1. Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients.
    Punyawudho B; Thammajaruk N; Ruxrungtham K; Avihingsanon A
    Int J Antimicrob Agents; 2017 Mar; 49(3):327-332. PubMed ID: 28109702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults.
    Hiransuthikul A; Thammajaruk N; Techatanawat I; Karachot B; Chuasuwan B; Manamuti C; Duereh M; Sawpitiporn M; Sophonphan J; Gatechompol S; Avihingsanon A; Bowonwattanuwong C; Ruxrungtham K;
    Antivir Ther; 2018; 23(8):699-703. PubMed ID: 30265243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients.
    Singkham N; Avihingsanon A; Brundage RC; Birnbaum AK; Thammajaruk N; Ruxrungtham K; Bunupuradah T; Kiertiburanakul S; Chetchotisakd P; Punyawudho B;
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):99-108. PubMed ID: 34727835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
    Schipani A; Dickinson L; Boffito M; Austin R; Owen A; Back D; Khoo S; Davies G
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):60-6. PubMed ID: 23011396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
    Foissac F; Blanche S; Dollfus C; Hirt D; Firtion G; Laurent C; Treluyer JM; Urien S
    Br J Clin Pharmacol; 2011 Dec; 72(6):940-7. PubMed ID: 21649692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
    Sevinsky H; Zaru L; Wang R; Xu X; Pikora C; Correll TA; Eley T
    Pediatr Infect Dis J; 2018 Jun; 37(6):e157-e165. PubMed ID: 29206748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
    Bunupuradah T; Techasaensiri C; Keadpudsa S; Thammajaruk N; Srimuan A; Sahakijpicharn T; Prasitsuebsai W; Ananworanich J; Puthanakit T;
    Pediatr Infect Dis J; 2014 Dec; 33(12):e316-9. PubMed ID: 24983717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
    Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
    Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.
    Moltó J; Estévez JA; Miranda C; Cedeño S; Clotet B; Valle M
    Br J Clin Pharmacol; 2016 Dec; 82(6):1528-1538. PubMed ID: 27447851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling.
    Montanha MC; Fabrega F; Howarth A; Cottura N; Kinvig H; Bunglawala F; Lloyd A; Denti P; Waitt C; Siccardi M
    Clin Pharmacokinet; 2022 Mar; 61(3):375-386. PubMed ID: 34635995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults.
    Avihingsanon A; van der Lugt J; Kerr SJ; Gorowara M; Chanmano S; Ohata P; Lange J; Cooper DA; Phanuphak P; Burger DM; Ruxrungtham K
    Clin Pharmacol Ther; 2009 Apr; 85(4):402-8. PubMed ID: 19118378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
    Zhu L; Hruska M; Hwang C; Shah V; Furlong M; Hanna GJ; Bertz R; Landry IS
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3816-22. PubMed ID: 25870057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of
    Singkham N; Avihingsanon A; Thammajaruk N; Ruxrungtham K; Bunupuradah T; Kiertiburanakul S; Chetchotisakd P; Burger DM; Emery S; Punyawudho B
    Pharmacogenomics; 2019 May; 20(7):517-527. PubMed ID: 31124411
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients.
    Gervasoni C; Riva A; Rizzardini G; Clementi E; Galli M; Cattaneo D
    Antivir Ther; 2015; 20(4):449-51. PubMed ID: 25279606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
    von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
    Lê MP; Mandelbrot L; Descamps D; Soulié C; Ichou H; Bourgeois-Moine A; Damond F; Lariven S; Valantin MA; Landman R; Faucher P; Tubiana R; Duro D; Meier F; Legac S; Bourse P; Mortier E; Dommergues M; Calvez V; Matheron S; Peytavin G
    Antivir Ther; 2015; 20(5):507-13. PubMed ID: 25599649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
    Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
    HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
    Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.
    Dumond JB; Chen J; Cottrell M; Trezza CR; Prince H; Sykes C; Torrice C; White N; Malone S; Wang R; Patterson KB; Sharpless NE; Forrest A
    CPT Pharmacometrics Syst Pharmacol; 2017 Feb; 6(2):128-135. PubMed ID: 28032946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.